
Manufacturer’s plans for equitable access to twice-yearly PrEP under fire
While plans for global access to lenacapavir, the twice-yearly injectable PrEP product which demonstrated extraordinary efficacy last year, have progressed unusually quickly, critics say that the arrangements are riddled with inconsistencies and will not …